Emergent loses out on $180M as U.S. cancels COVID-19 vaccine production contract

After a tumultuous several months with the word “troubled” regularly attached to its Baltimore plant, contract manufacturer Emergent BioSolutions is no longer making COVID-19 vaccines for the U.S. government.

Since April, the Maryland-based company has been steeped in controversy for ruining millions of COVID-19 vaccine doses because of cross-contamination as it produced shots for AstraZeneca and Johnson & Johnson from its hulking facility in Baltimore.